Clinical Trials Browser

Withdrawn × Melanoma × tremelimumab × Clear all

NCT04223648 2021-11-22

Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma

Phase EARLY_PHASE1 Withdrawn

Melanoma